Skip to content

Dopaminergic Modulation of Cognition and Psychomotor Function

Dopaminergic Modulation of Cognition and Psychomotor Function

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01218425
Enrollment
20
Registered
2010-10-11
Start date
2010-11-30
Completion date
2012-06-30
Last updated
2012-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dopamine Activity, Episodic Memory Consolidation, Response Preparation

Keywords

dopamine, EEG, episodic memory, contingent negative variation, response preparation, levodopa, methylphenidate

Brief summary

A recent study at our lab showed increased episodic memory consolidation and response readiness after treatment with methylphenidate in healthy volunteers. The investigators seek to replicate and extend these findings. Furthermore the pharmacological specificity of these effects will be studied. Since methylphenidate has an effect on two neurotransmitters, dopamine and noradrenaline, either could be responsible for the observed effects. In order to explore the dopaminergic contribution to this effect, the study proposed here includes not only methylphenidate but also levodopa/carbidopa, which only affects dopamine and not noradrenaline. In this study, 20 healthy males and females between 18 and 45 years of age will participate. They will be recruited via advertisements at Maastricht University and in local newspapers. Participants will be treated once with methylphenidate, once with levodopa/carbidopa and once with placebo. All medications will be administered orally with a capsule. It is hypothesized that methylphenidate and levodopa/carbidopa will both enhance episodic memory consolidation and improve response readiness

Interventions

DRUGMethylphenidate 40 mg

Oral dose 40 mg

DRUGLevodopa/carbidopa 125 mg

oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule

DRUGDomperidon 10 mg

Domperidon 10 mg

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female * 18 to 45 years of age * Healthy (i.e. absence of all

Exclusion criteria

), normal static binocular acuity (corrected or uncorrected), * Body mass index between 18.5 and 30 * Willingness to sign an informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Behavioral score on the Word learning test1 dayNumber of words recalled in the word learning test

Secondary

MeasureTime frameDescription
CNV amplitude1 dayAmplitude of the CNV wave in the EEG
Reaction time on the CNV1 dayReaction time in the response preparation task in which CNV is measured

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026